Tarsus Pharmaceuticals, Inc. SEC filings TARS
Tarsus Pharmaceuticals, Inc. has 676 filings in SEC EDGAR's recent list, going back to Aug 7, 2020. Its latest annual report, Form ARS, was filed on Apr 28, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 3, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 3, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Nov 21, 2023 | — |
| CORRESP | Letter to the SEC | Nov 17, 2023 | — |
| UPLOAD | Letter from the SEC | Nov 16, 2023 | — |
| UPLOAD | Letter from the SEC | Apr 18, 2023 | — |
| CORRESP | Letter to the SEC | Apr 13, 2023 | — |
| UPLOAD | Letter from the SEC | Mar 30, 2023 | — |
| EFFECT | Filing | Nov 5, 2021 | — |
| CORRESP | Letter to the SEC | Nov 3, 2021 | — |
| UPLOAD | Letter from the SEC | Nov 3, 2021 | — |
| EFFECT | Filing | Oct 15, 2020 | — |
| CERT | Filing | Oct 15, 2020 | — |
| SEC STAFF LETTER | Filing | Oct 14, 2020 | — |
| CORRESP | Letter to the SEC | Oct 13, 2020 | — |
| CORRESP | Letter to the SEC | Oct 13, 2020 | — |
| 8-A12B | Filing | Oct 13, 2020 | — |
| CORRESP | Letter to the SEC | Oct 9, 2020 | — |
| UPLOAD | Letter from the SEC | Oct 7, 2020 | — |
| CORRESP | Letter to the SEC | Oct 6, 2020 | — |
| CORRESP | Letter to the SEC | Sep 25, 2020 | — |
| UPLOAD | Letter from the SEC | Sep 24, 2020 | — |
| DRSLTR | Filing | Sep 14, 2020 | — |
| DRS/A | Filing | Sep 14, 2020 | — |
| SEC STAFF LETTER | Filing | Sep 4, 2020 | — |
| UPLOAD | Letter from the SEC | Sep 4, 2020 | — |
| DRS/A | Filing | Aug 14, 2020 | — |
| DRS | Filing | Aug 7, 2020 | — |
Showing 26 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- TARS (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Irvine, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1819790
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.